Abatacept in biologic-naïve patients and TNF inadequate responders: Clinical data in focus

Current Medical Research and Opinion

Volumn 24, Issue 8, 2008, Pages 2283-2294

  Sherrer, Yvonne ^a  

^a Center for Rheumatology Immunology and Arthritis   (United States)

Author keywords

Abatacept; Co stimulation modulator; Cytotoxic T lymphocyte associated antigen 4 immunoglobulin; Rheumatoid arthritis

Indexed keywords

ABATACEPT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ETANERCEPT; METHOTREXATE; PLACEBO; T LYMPHOCYTE RECEPTOR;

ANTIGEN PRESENTING CELL; BENIGN TUMOR; BINDING AFFINITY; BREAST CANCER; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COUGHING; DIZZINESS; DRUG DOSE COMPARISON; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FLUSHING; HUMAN; HYPERTENSION; INFLUENZA; LUNG CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; NAUSEA; PATHOGENESIS; PRURITUS; QUALITY OF LIFE; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SNORING; T LYMPHOCYTE ACTIVATION; URINARY TRACT INFECTION; URTICARIA; WHEEZING;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOCONJUGATES; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 50149117950     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802223129     Document Type: Review

References (50)

1. Wyeth. Enbrel® (etanercept) for subcutaneous injection. Prescribing information. Available at http://www.enbrel.com [last accessed October 13, 2007]
2. Centocor. Remicade® (infliximab) for IV Injection. Prescribing information. Available at http://www.remicade.com/pdf/HCP_PPI.pdf [last accessed November 13, 2007]
3. Abbott. Laboratories Pharmaceutical Products Group. Humira® (adalimumab). Prescribing information. Available at http://www.humira.com [last accessed November 13, 2007]
4. Amgen. Kineret® (anakinra). Prescribing information. Available at http://www.kineretrx.com [last accessed March 2008]
5. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases. Ann Rheum Dis 2007;66(Suppl 3):iii2-iii22
6. Verstappen SM, Poole AR, Ionescu M, et al. Radiographic joint damage in rheumatoid arthritis is associated with differences in cartilage turnover and can be predicted by serum biomarkers: an evaluation from 1 to 4 years after diagnosis. Arth Res Ther 2006;8:R31
7. Keystone EC. Strategies to control disease in rheumatoid arthritis with tumor necrosis factor antagonists - an opportunity to improve outcomes. Nate Clin Pract 2006;2:594-601
8. Mader R, Keystone E. Optimizing treatment with biologics. J Rheumat 2007;80:16-24
9. Yamaguchi Y, Yamamoto K. New therapeutic strategy of rheumatoid arthritis to reach the goal of suppression of joint destruction. Clin Calc 2007;17:463-73
10. Cush JJ. Early rheumatoid arthritis - is there a window of opportunity? J Rheumatol 2007;80:1-7
11. Smolen JS, Han C, Bala M, et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 2005;52:1020-30
12. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81
13. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400-11
14. Keystone EC, Kavanaugh A. What to do with TNF failures. Expert Opin Drug Saf 2005;4:149-55
15. Durez P, Van den Bosch F, Corluy L, et al. A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study. Rheumatol 2005;44:465-8
16. Emery P, Kosinski M, Li T, et al. Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life. J Rheumatol 2006; 33:681-9
17. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis [Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group]. New Engl J Med 2000;343:1594-602
18. Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2003;2:473-88
19. Pettit AR, Thomas R. Dendritic cells: the driving force behind autoimmunity in rheumatoid arthritis? Immunol Cell Biol 1999;7:420-7
20. Bretscher PA. A two-step, two-signal model for the primary activation of precursor helper T cells. Proc Natl Acad Sci USA 1999;96:85-90
21. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. New Engl J Med 2001;344:907-16
22. Yamada A, Salama AD, Sayegh MH. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J Am Soc Nephrol 2002;13:559-75
23. Kremer JM, Dougados M, Emery P, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:2263-71
24. Davies P, Zhou L, Abraham R. Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity. J Rheumatol 2007;34:280-9
25. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis. Ann Intern Med 2006;144:865-76
26. Moreland LW, Alten R, Van den Bosch F, et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 2002;46:1470-9
27. Weinblatt ME, Schiff MH, Goldman A, et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomized clinical trial. Ann Rheum Dis 2007;66:228-34
28. Weisman MH, Durez P, Hallegua D, et al. Reduction of inflammatory biomarker response by abatacept in the treatment of rheumatoid arthritis. J Rheumatol 2006;33:2162-6
29. Genovese MC, Becker JC, Schiff M, et al, Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. New Engl J Med 2005;353:1114-23
30. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. New Engl J Med 2003;349:1907-15
31. Salaffi F, Stancati A. Disability and quality of life of patients with rheumatoid arthritis: assessment and perspectives. Reumatismo 2004;56:87-106
32. Russell AS, Wallenstein GV, Li T, et al. Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment. Ann Rheum Dis 2007;66:189-4
33. Wells G, Li T, Maxwell L, et al. Determining the minimal clinically important differences in activity, fatigue, and sleep quality in patients with rheumatoid arthritis. J Rheumatol 2007; 34:280-9
34. Westhovens R, Cole JC, Li T, et al. Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial. Rheumatology (Oxford) 2006;45:1238-46
35. Weinblatt M, Combe B, Covucci A, et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and noribiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum 2006;54:2807-16
36. Genovese MC. Biologic therapies in clinical development for the treatment of rheumatoid arthritis. J Clin Rheumatol 2005;11:S45-S54
37. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. New Engl J Med 2000;343:1586-93
38. Baumgartner SW, Fleischmann RM, Moreland LW, et al. Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability. J Rheumatol 2004;31:1532-7
39. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randornised controlled trial. Lancet 2004;364:263-9
40. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90
41. Pincus T, Yazici Y, Sokka T. Quantitative measures of rheumatic diseases for clinical research versus standard clinical care: differences, advantages and limitations. Best Pract Res 2007;21:601-28
42. Wolfe F, Michaud K. Fatigue, rheumatoid arthritis, and anti-tumor necrosis factor therapy: an investigation in 24 831 patients. J Rheumatol 2004;31:2115-20
43. Fraenkel L, Bogardus ST, Concato J, et al. Patient preferences for treatment of rheumatoid arthritis. Ann Rheum Dis 2004;63:1372-8
44. Repping-Wuts H, Uitterhoeve R, van Riel P, et al. Fatigue as experienced by patients with rheumatoid arthritis (RA): a qualitative study. Int J Nurs Stud 2007 Jul 25 [Epub ahead of print]
45. Carr A, Hewlett S, Hughes R, et al. Rheumatology outcomes: the patient's perspective. J Rheumatol 2003;30:880-3
46. Albers JM, Kuper HH, van Riel PL, et al. Socio-economic consequences of rheumatoid arthritis in the first years of the disease. Rheumatology (Oxford) 1999;38:423-30
47. Genovese MC, Cohen S, Moreland L, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004;50: 1412-9
48. Ries L, Eisner M, Kosary C, et al. SEER cancer statistics review, 1975-2001. National Cancer Institute, Bethesda, MD. Available at: http://seer.cancer.gov/csr/1975_2004/[last accessed February 28, 2008]
49. Mellemkjaer L, Linet MS, Gridley G, et al. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996;32A:1753-7
50. Shekelle PG, Woolf SH, Eccles M, et al. Clinical guidelines: developing guidelines. Br Med J (Clin Res Ed) 1999; 318:593-6